Thomas Boike, MD
Radiation Oncology · Clarkston, MINPI 1699970525
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Progenics Pharmaceuticals, Inc. at 44.5% of the total. Reporting peaked in 2023 at $101,611 and has fallen 93.0% since, to $7,139 in 2024. Among radiation oncology clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $663.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Progenics Pharmaceuticals, Inc.$76K
- Palette Life Sciences, Inc.$39K
- Myovant Sciences Inc.$12K
- Pfizer$11K
- Boston Scientific$9K
- Elekta, Inc.$6K
- plus $18K from 27 others
Across 64 payments — averaging $16,794 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Palette Life Sciences, Inc.$807K
- Boston Scientific$128K
- Pfizer$75K
- Sumitomo Pharma America, Inc.$36K
- Novartis$16K
- AstraZeneca$11K
- plus $1K from 1 others
What the payments were for
- Consulting fees$53,79932%
- Speaking & faculty fees$87,51251%
- Grants$1,5001%
- Travel & lodging$18,97711%
- Food & beverage$8,8075%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Progenics Pharmaceuticals, Inc. | 91 | $75,968 |
| Palette Life Sciences, Inc. | 39 | $38,735 |
| Myovant Sciences Inc. | 12 | $11,585 |
| Pfizer | 13 | $11,221 |
| Boston Scientific | 20 | $9,387 |
| Elekta, Inc. | 14 | $5,773 |
| AstraZeneca(2 entities) | 7 | $3,319 |
| Telix Pharmaceuticals | 2 | $2,909 |
| Blue Earth Diagnostics | 7 | $2,772 |
| Photocure Inc | 2 | $2,506 |
| Sumitomo Pharma America, Inc. | 13 | $1,870 |
| Molli Surgical (US) Inc | 2 | $1,852 |
| Novartis | 5 | $1,763 |
| Bayer | 7 | $273 |
| Viewray Technologies Inc | 1 | $107 |
| Incyte Corporation | 1 | $100 |
| Genentech USA, Inc. | 3 | $58 |
| Varian Medical Systems, Inc. | 1 | $39 |
| Medivation Services LLC | 1 | $38 |
| Philips North America LLC | 1 | $38 |
| Brainlab, Inc. | 2 | $37 |
| Myriad Genetic Laboratories, Inc. | 2 | $34 |
| Exelixis Inc. | 1 | $25 |
| Seagen Inc. | 1 | $24 |
| Servier Pharmaceuticals LLC | 1 | $22 |
| EMD Serono, Inc. | 1 | $20 |
| Amgen | 1 | $19 |
| AVEO Pharmaceuticals, Inc. | 1 | $19 |
| Novocure Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Foundation Medicine, Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $17 |
| Fortovia Therapeutics, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PYLARIFY$74,620
- ELEKTA MEDICAL LINEAR ACCELERATOR$20,453
- ORGOVYX$19,566
- SPACEOAR VUE$5,870
- XTANDI$4,725
- Clarity$3,347
- IMFINZI$3,150
- ILLUCCIX$2,909
- Axumin$2,625
- Cysview$2,506
- SPACEOAR$2,459
- ELEKTA UNITY$1,950
- SpaceOAR VUE System - 10mL$581
- PLUVICTO$134
- Unity$120
- Versa HD$113
- Mosaiq$113
- SYNERGY$113
- METRIQ$113
- INFINITY$113
How this compares
$170,595 in reported general payments places this provider in the 95th percentile of 198 radiation oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 17 | $43,324 |
| Tamsulosin Hcl | 20 | $431 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx | $1,870 | $43,32417 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 198 radiation oncology providers in Michigan.
Other radiation oncology in Clarkston
- Frank ViciniPontiac$231K
- Farzan SiddiquiDetroit$72K
- Daniel WahlAnn Arbor$42K
- Daniel ChangAnn Arbor$38K
- Shruti JollyAnn Arbor$30K
- Brandon ManciniGrand Rapids$30K
- Alvaro MartinezFarmington Hills$24K
- James KaneAnn Arbor$19K
- M Salim SiddiquiDetroit$17K
- Parag ParikhDetroit$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.